Table 1.
Characteristics of CVC developing or not catheter-related bloodstream infection (CRBSI) and developing or not primary bloodstream infections (PBSI).
| Data | Non CRBSI (n=84) | CRBSI(n=10) | P-value CRBSI vs non | Non PBSI(n=71) | PBSI (n=23) | P-value PBSI vs non |
|---|---|---|---|---|---|---|
| Time of CVC (days); median (p 25-75) | 9 (7-12) | 10 (9-13) | 0.31 | 9 (7-12) | 9 (8-12) | 0.75 |
| Site of CVC; n (%) | 0.71 | 0.83 | ||||
| Subclavian | 18 (21.4) | 3 (30.0) | 15 (21.1) | 6 (26.1) | ||
| Jugular | 45 (53.6) | 4 (40.0) | 37 (52.1) | 12 (52.2) | ||
| Femoral | 21 (25.0) | 3 (30.0) | 19 (26.8) | 5 (21.7) | ||
| Age; years (p 25-75) | 65 (54-72) | 64 (52-71) | 0.74 | 64 (54-72) | 64 (52-72) | 0.80 |
| Sex female; n (%) | 23 (27.4) | 0 | 0.11 | 20 (28.2) | 3 (13.0) | 0.17 |
| Admission diagnostic; n (%) | 0.38 | 0.07 | ||||
| Medical | 63 (75.0) | 9 (90.0) | 51 (71.8) | 21 (91.3) | ||
| Surgical | 14 (16.7) | 0 | 14 (19.7) | 0 | ||
| Traumatology | 7 (8.3) | 1 (10.0) | 6 (8.5) | 2 (8.7) | ||
| Diabetes mellitus; n (%) | 23 (27.4) | 4 (40.0) | 0.47 | 23 (32.4) | 4 (17.4) | 0.20 |
| Renal replacement therapy previously to admission ;n (%) | 3 (3.6) | 1 (10.0) | 0.37 | 2 (2.8) | 2 (8.7) | 0.25 |
| COPD; n (%) | 10 (11.9) | 0 | 0.59 | 7 (9.9) | 3 (13.0) | 0.70 |
| Asthma; n (%) | 4 (4.8) | 1 (10.0) | 0.44 | 3 (4.2) | 2 (8.7) | 0.59 |
| Chronic liver disease; n (%) | 4 (4.8) | 0 | 0.99 | 4 (5.6) | 0 | 0.57 |
| Smoking; n (%) | 14 (16.7) | 1 (10.0) | 0.99 | 11 (15.5) | 4 (17.4) | 0.99 |
| Parenteral nutrition previously to admission; n (%) | 1 (1.2) | 0 | 0.99 | 1 (1.4) | 0 | 0.99 |
| Corticosteroids previously to admission; n (%) | 3 (3.6) | 0 | 0.99 | 3 (4.2) | 0 | 0.99 |
| Immunosuppressive therapy previously to admission; n (%) | 4 (4.8) | 1 (10.0) | 0.44 | 4 (5.6) | 1 (4.3) | 0.99 |
| Hematological tumor; n (%) | 0 | 1 (10.0) | 0.11 | 0 | 1 (4.3) | 0.25 |
| Solid tumor; n (%) | 1 (1.2) | 0 | 0.99 | 1 (1.4) | 0 | 0.99 |
| Human Immunodeficiency Virus; n (%) | 1 (1.2) | 0 | 0.99 | 1 (1.4) | 0 | 0.99 |
| Corticosteroids at sepsis; n (%) | 12 (14.3) | 0 | 0.35 | 8 (11.3) | 4 (17.4) | 0.48 |
| Immunosuppressive therapy at sepsis; n (%) | 2 (2.4) | 0 | 0.99 | 2 (2.8) | 0 | 0.99 |
| Parenteral nutrition at sepsis; n (%) | 14 (16.7) | 2 (20.0) | 0.68 | 10 (14.1) | 6 (26.1) | 0.21 |
| Propofol at sepsis; n (%) | 34 (40.5) | 4 (40.0) | 0.99 | 31 (43.7) | 7 (30.4) | 0.33 |
| Renal replacement therapy at sepsis; n (%) | 7 (8.3) | 1 (10.0) | 0.99 | 7 (9.9) | 1 (4.3) | 0.67 |
| Deaths at 30 days; no. (%) | 23 (27.4) | 3 (30.0) | 0.99 | 20 (28.2) | 6 (26.1) | 0.99 |
CVC = central venous catheter; COPD = Chronic Obstructive Pulmonary Disease